Project description
Antibody therapy against COVID-19
Passive immunotherapy, through the transfer of antibodies, has been proposed as a potential approach for treating patients with COVID-19. Building on previous experience of antibody therapy against SARS- and MERS-CoV, scientists of the EU-funded ATAC project will characterise human antibodies obtained from the blood of recovered coronavirus patients from China and Italy. Using a combination of experimental and computational work, they will optimise, produce and test all antibodies before selecting the most effective candidate for therapy. The rapid dissemination of the project's results will help the medical community respond to the current COVID-19 pandemic through improved patient management.
Programme(s)
Call for proposal
H2020-SC1-PHE-CORONAVIRUS-2020
See other projects for this call
Funding Scheme
RIA - Research and Innovation actionCoordinator
17177 Stockholm
Sweden
Participants (4)
6500 Bellinzona
1049 Brussels
38106 Braunschweig
27100 Pavia
